Cogent Biosciences, Inc.
COGT
$4.98
$0.265.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -269.50M | -255.86M | -242.30M | -227.05M | -212.17M |
| Total Depreciation and Amortization | 4.42M | 4.35M | 4.04M | 3.80M | 3.93M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.18M | 32.12M | 29.31M | 34.81M | 28.65M |
| Change in Net Operating Assets | 10.12M | 11.60M | 17.67M | 11.17M | 12.96M |
| Cash from Operations | -221.77M | -207.79M | -191.28M | -177.27M | -166.64M |
| Capital Expenditure | -1.05M | -573.00K | -813.00K | -654.00K | -1.76M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 107.66M | 38.85M | -12.09M | -162.97M | -154.90M |
| Cash from Investing | 106.61M | 38.28M | -12.91M | -163.63M | -156.66M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 37.06M | 226.15M | 226.03M | 226.40M | 387.85M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00K | -100.00K | -11.60M | -11.60M | -10.70M |
| Cash from Financing | 25.36M | 214.45M | 214.43M | 214.80M | 377.15M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -89.80M | 44.94M | 10.24M | -126.10M | 53.85M |